Related references
Note: Only part of the references are listed.SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/- mice
Damilola D. Adingupu et al.
CARDIOVASCULAR DIABETOLOGY (2019)
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Hsiang-Chun Lee et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Akira Sezai et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Munemitsu Otagaki et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial
Milton Packer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Carol Pollock et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Nannan Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial
Michael E. Nassif et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
Sook Jung Lee et al.
JOURNAL OF OBESITY & METABOLIC SYNDROME (2019)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
Jasper Tromp et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
Fumitaka Soga et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Volume Overload Profiles in Patients With Preserved and Reduced Ejection Fraction Chronic Heart Failure Are There Differences? A Pilot Study
Wayne L. Miller et al.
JACC-HEART FAILURE (2016)
Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus
Yasuhide Mochizuki et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside
Sunder Mudaliar et al.
DIABETES CARE (2015)
Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction
Sandra Sanders-van Wijk et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging
Jens-Uwe Voigt et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Roberto M. Lang et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Longitudinal Myocardial Strain Alteration Is Associated with Left Ventricular Remodeling in Asymptomatic Patients with Type 2 Diabetes Mellitus
Laura Ernande et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2014)
2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus: Is It Really the First Marker of Diabetic Cardiomyopathy?
Laura Ernande et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2011)
The Development of Heart Failure in Patients With Diabetes Mellitus and Pre-Clinical Diastolic Dysfunction A Population-Based Study
Aaron M. From et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Share Paper
